Abstract 1568P
Background
Lung cancer (LC) screening is an effective secondary preventive measure in decreasing LC mortality. Except for age and smoking history prediction models with additional variables were verified in different populations. In September 2020 the first pilot program for early detection of LC started in Vojvodina, Serbia. To increase LC positive findings we analyze characteristics of screening participants from September 2020 to April 2024.
Methods
Eligibility for LC screening is restricted to persons aged 50-74 years, with a smoking history of 30 pack-years, or 20 pack-years with additional risks; either active or quit smoking within the previous 10 years. Participants sign informed consent and fill out an online questionnaire with socio-demographic data (age, gender, marital, education, working status), smoking status (pack-years), exposure data (professional, tobacco exposure in childhood, in adulthood), BMI, alcohol consumption, symptoms of respiratory diseases, presence of chronic disease or cancer of other localization, and family history of LC. Screening results were reported by Lung RADS score (1 to 4). Differences between participants with positive (score 4) and negative or intermediate (score 1 to 3) results were analyzed.
Results
During the observed period, 61.3% (1690/2759) of screened were females. Positive screens were reported in 264(9.6%) of participants. Characteristics of participants divided by scores (4 vs score 1-3) showed differences in age (64.03±6.62 vs 61.54±6.71, p<0.001), BMI (25.35±3.87 vs 26.64±4.58, p<0.001), years of smoking (38.82±9.47 vs 37.01±8.60, p=0.001), pack-years (42.59±17.06 vs 39.49±16.20, p=0.003), appetite loss (11.4% vs 6.7%, p=0.005), and weight loss (14.4% vs 8.1%, p<0.001). Significant differences were observed between participants according to employment (p<0.001) and education level (p=0.022); retired (60.6% vs 44.3%) and finished primary school (14.0% vs 8.6%) were more common in score 4, while employed (43.2% vs 27.3%) and faculty education (23.7% vs 19.7%) in score 1-3.
Conclusions
Reaching more elderly and heavy smoker participants with lower BMI and lower education could increase the percentage of LC positive screening results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Pulmonary Diseases of Vojvodina.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10